Analysis

Filter
Clear Filter

Last week, we added IQVIA Holdings (NYSE: IQV) to our portfolio. The company was previously known as QuintilesIMS until November 15. On that date, the company changed its name and stock symbol to their present form. The company itself was formed via merger in 2016 between Quintiles and IMS Health,… Read More

We hope everyone spent a wonderful day with family and enjoyed a hearty meal! With Thanksgiving behind us, it’s time to focus on the markets again. Today we discuss the first of the two recent portfolio additions. We will take a look at XPO Logistics (NYSE: XPO) today and IQVIA… Read More

Before we discuss Jazz Pharmaceuticals (Nasdaq: JAZZ), we want to give you a quick update on the latest changes in our reference funds’ holdings of Brain Trust Portfolio stocks. The latest Form 13Fs have just been filed. The most notable change is that Shapiro Capital Management its slashed… Read More

ViaSat (Nasdaq: VSAT) reported its fiscal 2018 second quarters on Wednesday after the market close. Revenues of $393.1 million missed The Street’s expectation by roughly $9 million, but the company posted a surprising profit, earnings $0.09 per share, beating expectations for a $0.03 loss. After dipping at the open the… Read More

ChannelAdvisor (NYSE: ECOM) reported third-quarter results yesterday. After two good quarters to begin 2017, the third was unfortunately a disappointment. Plus, the company issued fourth-quarter guidance below analysts’ expectations. The end result is a steep decline in the stock price today. Revenues grew 8 percent year-on-year to $30.1 million. Variable… Read More

TAL Education (NYSE: TAL) reported fiscal 2018 second-quarter revenues of $456 million, a 68 percent year-over-year improvement, and earnings of $0.12 per ADR. Overall enrollment more than doubled. In local currency, renminbi (RMB) (removing the impact of the foreign-exchange rate by converting into dollar terms), the growth is actually an… Read More

Recent Brain Trust Profits addition Synchrony Financial (NYSE: SYF) gained roughly 4 percent on Friday after reporting strong third-quarter results. The company’s third-quarter net revenues (net interest income) increased 11 percent compared to a year ago to $3.88 billion. Net earnings of $555 million (or $0.70 per share) was 8.1… Read More

Earlier today we welcomed Angiodynamics (Nasdaq: ANGO) to our portfolio, following the lead of BlackRock (NYSE: BLK), which has continued to accumulate shares in the company. The medical device maker has expanded from its humble beginnings in upstate New York into a global supplier with international presence in Europe and… Read More

Following the lead of two highly successful investing gurus dubbed “oracles” by Wall Street, we have just added Synchrony Financial (NYSE: SYF) to our portfolio. Both the Oracle of Omaha, Warren Buffett, and the Oracle of Boston, Seth Klarman, hold large stakes in the company. Buffett’s Berkshire Hathaway (NYSE: BRK.B)… Read More

ViaSat (Nasdaq: VSAT) has completed the Critical Design Review (CDR) for its ViaSat-3 class spacecraft, and is ready to move to the building, integration and testing phase for the first two (of three) satellites to be deployed. The company will once again work with Boeing (NYSE: BA) to build the… Read More

New pick Jazz Pharmaceuticals (Nasdaq: JAZZ) specializes in treating ailments related to sleep disorders and has an expanding portfolio focused on cancers of the blood. The shares are modestly valued by the market, and offer interesting potential upside. Read on for more details. Read More

Last Friday we highlighted BYD Company (OTCMKTS: BYDDF) as a buying opportunity as it traded around $6 a share. Our timing could not have been better: a day later, the vice minister of China’s Ministry of Industry and Information Technology stated that the Chinese government is working on a timetable… Read More

BYD Company (OTCMKTS: BYDDF) briefly fell below $6 per share earlier this week before rebounding a bit. Since reaching a 3-month peak in late July, the shares have been under some pressure. Let’s take a look at how the company is faring. In the first half of 2017, BYD had… Read More

Our three new picks this month got off to a bit of a slow start, but they have all recovered very nicely. What’s more, due to the stocks’ price action, most of our readers probably were able to buy shares of these new recommendations at better entry prices than we… Read More

We have had good success following Chase Coleman III’s Tiger Global in the past and this week, we again added a top holding from the hedge fund to our portfolio: TAL Education (NYSE: TAL), a leading operator in a booming industry in China: private tutoring. In China, the job market… Read More

Earlier this week, we added two new high-conviction picks from top money managers. We added ViaSat (Nasdaq: VSAT) from Baupost Group and ChannelAdvisor (NYSE: ECOM) from Shapiro Capital Management. This is the second time we have recommended ViaSat. It was one of our very first recommendations in Brain Trust Profits. Read More

Sotheby’s (NYSE: BID) took a tumble after reporting disappointing second-quarter earnings. For the first time since February 2016, the stock fell in reaction to earnings. The company booked revenues of $314.9 million during the quarter, slightly below The Street’s expectation for $315.7 million. The roughly $315 million figure represents a… Read More

This week, Republic Services (NYSE: RSG) reported a 7.5 percent year-over-year revenue increase in the second quarter was the best growth rate in eight years. Earnings per share (adjusted for non-recurring items) of $0.61 was a 10.9 percent improvement over the second quarter of 2016. Average yield increased 2.5 percent,… Read More

This week our biotech pick Theravance Biopharma (Nasdaq: TBPH) announced the results of its 12-month long Phase 3 study of revefenacin (TD-4208), jointly conducted with Mylan (Nasdaq: MYL). As we discussed in the June 9 weekly issue, the results released earlier this year from the first two Phase 3 studies… Read More